Umedica Company Profile
What is the competitive landscape for UMEDICA
UMEDICA has sixteen approved drugs.
There is one tentative approval on UMEDICA drugs.
Drugs and US Patents for Umedica
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Umedica | TADALAFIL | tadalafil | TABLET;ORAL | 211298-001 | Oct 23, 2020 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | TADALAFIL | tadalafil | TABLET;ORAL | 211298-004 | Oct 23, 2020 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 219946-002 | Aug 4, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | DICLOFENAC POTASSIUM | diclofenac potassium | TABLET;ORAL | 215750-001 | May 11, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 214551-001 | Aug 5, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Umedica | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 213853-001 | Aug 19, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

